Reducing B cell activity may help alleviate chronic inflammation and prevent further ECM degradation in IDD. B cell-specific therapies, including BTK inhibitors and CAR-T cells, represent advanced strategies to target B cell-driven pathology in chronic diseases like IDD. Here, BTK is linked to intervertebral disk degenerative disorder.